Adagene Inc. (ADAG) stock
Close on Nov 12, 2026Market cap $118.46MP/E –Yield –
Adagene Inc. grew revenue 7332.8% to $7.67M over fiscal 2025. Free cash flow was -$15.67M. At the latest close the market valued the company at $118.46M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $118.46M
- P/E ratio
- –
- Price to sales
- 15.44
- Price to book
- 1.32
- Dividend yield
- –
- Free cash flow yield
- -13.23%
Fundamentals
- Revenue
- $7.67M
- Net income
- -$17.61M
- EPS, diluted
- -$0.30
- Free cash flow
- -$15.67M
Trading
- Previous close
- $2.13
- Open
- $2.11
- Day's range
- $1.91 – $2.28
- Volume
- 278,128
- Average volume (20 days)
- 187,125
- Beta (5 years)
- 0.76
- 52-week range
- $1.50 – $4.85
- RSI (14 days)
- 36.2
- Volatility (1 year)
- 92.1%
- Relative volume
- 1.06×
- WACC
- 8.6%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADAG | S&P 500 | Difference | ADAG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -27.0% | -2.7% | −24.3 pts | ||
| 3 months | -46.7% | -1.7% | −44.9 pts | ||
| Year to date | +5.8% | +11.9% | −6.1 pts | ||
| 1 year | +13.0% | +12.0% | +1.0 pts | ||
| 3 years | +38.9% | +78.2% | −39.3 pts | +11.6% | +21.2% |
| 5 years | -81.8% | +73.2% | −155.1 pts | -28.9% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Adagene filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Adagene
Pharmaceutical Preparations
Adagene Inc. is a clinical-stage biotechnology company that discovers and develops antibody-based cancer immunotherapies using computational biology. The company utilizes proprietary antibody platforms, including its Dynamic Precision Library, to engineer masked and empowered antibodies such as NEObodies, SAFEbodies, and POWERbodies. Its product pipeline includes clinical candidates like ADG126, an anti-CTLA-4 therapy undergoing clinical trials for solid tumors such as colorectal cancer, alongside earlier-stage candidates including ADG206, ADG138, and ADG116. Adagene collaborates with and out-licenses technologies to global pharmaceutical and biotechnology partners, academic institutions, and healthcare organizations.
Company profile, executives and historyAdagene stock: common questions
What is Adagene's stock price?
ADAG closed at $2.00 on Nov 12, 2026, down 6.10% on the day. Over the past 52 weeks it traded between $1.50 and $4.85.
What is Adagene's market cap?
Adagene was worth $118.46M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ADAG's P/E ratio?
Adagene lost money over fiscal 2025 (diluted EPS -$0.30), so it has no meaningful P/E ratio.
How much revenue does Adagene make?
Adagene reported revenue of $7.67M for fiscal 2025, up 7332.8% from a year earlier.
Does Adagene pay a dividend?
No. Adagene has not paid a cash dividend over the last twelve months.
How has ADAG stock performed over the past year?
Including dividends, ADAG returned +13.0% over the past year, against +12.0% for the S&P 500.
Who are Adagene's competitors?
Companies most similar to Adagene by business, industry and size include CBIO, APLM, IMNM, CTMX, BOLT.
See a number that looks wrong?